It is unclear if the patient’s anti-tumor efficacy is due to the deleterious BRCA1 mutation and response to PARP inhibition and if this was enough to overcome the trend towards poorer OS and PFS we saw in patients with PTEN mutations This case illustrates the complexity and personalized nature of cancer treatment responses and the need for more in depth analysis. This evidence concerns the gene PARP1 and neoplasm.